<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-1EH69OLL</identifier><date>2020</date><creator>Anderluh, Marko</creator><creator>Jakopin, Žiga</creator><creator>Tomašič, Tihomir</creator><relation>documents/doc/1/URN_NBN_SI_doc-1EH69OLL_001.pdf</relation><relation>documents/doc/1/URN_NBN_SI_doc-1EH69OLL_001.txt</relation><format format_type="issue">2</format><format format_type="volume">71</format><format format_type="type">article</format><format format_type="extent">str. 133-140</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">21003267</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-1EH69OLL</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">covid-19</subject><subject language_type_id="slv">koronavirus</subject><subject language_type_id="slv">Pandemije</subject><subject language_type_id="slv">protivirusne učinkovine</subject><subject language_type_id="slv">SARS-CoV-2</subject><subject language_type_id="slv">Virusne infekcije</subject><title>Antiviral drugs against SARS-CoV-2 for the treatment of covid-19</title><title>Protivirusne učinkovine proti SARS-CoV-2 za zdravljenje bolezni covid-19</title></Record>